Tuesday, December 15, 2020

ACELYRIN Snags Funding For Biotech Effort

Los Angeles-based ACELYRIN, a new startup biopharma company, announced this morning that it has raised a Series A funding. Size of the funding round was not announced. The funding came from Westlake Village BioPartners. ACELYRIN said it is focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating development and commercialization of promising drug candidates. The company was co-founded by Shao-Lee Lin, MD, PhD, and Bob Carey. The company is initially focused on immunology. According to ACELYRIN, the company's co-founders previously worked on medicines such as Skyrizi, Rinvoq, Tepezza, Mavyret, Krystexxa, Humira, and Enbrel. Beth Seidenberg, MD, co-founding managing director of Westlake Village BioPartners, has joined ACELYRIN's board as part of the funding.